文献速递消化、代谢与肾脏急症心脑血管急症

利格列汀与安慰剂对心血管高危和肾脏高危的2型糖尿病成人主要心血管事件的影响:CARMELINA随机临床试验

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
PubMed 文献 · JAMA · 2019-01-01
一句话结论在心血管和肾脏高危的2型糖尿病成人中,利格列汀5 mg每日一次较安慰剂不劣于主要心血管复合终点(HR 1.02;95%CI 0.89-1.17;非劣效性P<.001)。

CARMELINA是一项随机、安慰剂对照、多中心非劣效性试验,纳入6991例心血管高危和肾脏高危的2型糖尿病成人,随机接受利格列汀5 mg每日一次(n=3494)或安慰剂每日一次(n=3485)加常规治疗。中位随访2.2年,主要心血管复合终点(心血管死亡、非致死性心肌梗死或非致死性卒中)在利格列汀组和安慰剂组分别发生434例(12.4%)和420例(12.1%),绝对发生率差为0.13/100人年(95%CI -0.63至0.90),HR 1.02(95%CI 0.89-1.17;非劣效性P<.001);肾脏复合终点分别发生327例(9.4%)和306例(8.8%),HR 1.04(95%CI 0.89-1.22;P=.62)。利格列汀组和安慰剂组不良事件发生率分别为77.2%和78.1%,低血糖发生率分别为29.7%和29.4%,经裁定确认的急性胰腺炎事件分别为9例(0.3%)和5例(0.1%)。

要点

  • 在心血管和肾脏高危的2型糖尿病成人中,利格列汀5 mg每日一次加常规治疗较安慰剂加常规治疗,主要心血管复合终点非劣效(HR 1.02;95%CI 0.89-1.17;非劣效性P<.001)。
  • 利格列汀组主要心血管复合终点发生率为12.4%(434/3494),安慰剂组为12.1%(420/3485),绝对发生率差为0.13/100人年(95%CI -0.63至0.90)。
  • 肾脏复合终点(肾衰竭死亡、终末期肾病或eGFR持续下降≥40%)在利格列汀组和安慰剂组分别为9.4%(327/3494)和8.8%(306/3485),HR 1.04(95%CI 0.89-1.22;P=.62)。
  • 利格列汀组与安慰剂组不良事件发生率分别为77.2%(2697例)和78.1%(2723例),低血糖发生率分别为29.7%(1036例)和29.4%(1024例)。
  • 经裁定确认的急性胰腺炎事件在利格列汀组为9例(0.3%),安慰剂组为5例(0.1%)。

适用人群与场景

  • 2型糖尿病成人,糖化血红蛋白6.5%至10.0%,心血管高危(有血管疾病史且尿白蛋白肌酐比[UACR]>200 mg/g),肾脏高危(eGFR降低合并微量或大量白蛋白尿)。
  • 排除终末期肾病(ESRD)患者;研究在27个国家605个临床中心进行。

诊断标准与关键阈值

  • 非劣效性标准:利格列汀相对安慰剂的风险比(HR)双侧95%CI上限小于1.3。

处置流程与药物剂量

  • 利格列汀5 mg每日一次(n=3494)或安慰剂每日一次(n=3485),均加于常规治疗;可根据临床需要和当地临床指南加用其他降糖药物或胰岛素。

研究设计与关键结果

  • 研究类型:随机、安慰剂对照、多中心非劣效性试验;纳入6991例受试者,6979例(平均年龄65.9岁;eGFR 54.6 mL/min/1.73 m2;80.1% UACR>30 mg/g)至少接受1剂研究药物,98.7%完成研究;中位随访2.2年。
  • 主要终点(首次发生心血管死亡、非致死性心肌梗死或非致死性卒中的复合终点):利格列汀组434/3494(12.4%) vs 安慰剂组420/3485(12.1%),绝对发生率差0.13/100人年(95%CI -0.63至0.90),HR 1.02(95%CI 0.89-1.17;非劣效性P<.001)。
  • 肾脏终点(首次发生裁定肾衰竭死亡、ESRD或eGFR较基线持续下降≥40%):利格列汀组327/3494(9.4%) vs 安慰剂组306/3485(8.8%),绝对发生率差0.22/100人年(95%CI -0.52至0.97),HR 1.04(95%CI 0.89-1.22;P=.62)。
  • 不良事件:利格列汀组2697例(77.2%) vs 安慰剂组2723例(78.1%);低血糖至少1次发作:利格列汀组1036例(29.7%) vs 安慰剂组1024例(29.4%);经裁定确认的急性胰腺炎事件:利格列汀组9例(0.3%) vs 安慰剂组5例(0.1%)。

证据类型、等级与局限

  • 证据类型:随机对照试验(非劣效性设计)。

对床旁实践的改变

  • 作者认为,在心血管和肾脏高危的2型糖尿病成人中,利格列汀加常规治疗较安慰剂加常规治疗,中位2.2年内心血管复合终点风险非劣效。

指南或共识出处

  • CARMELINA随机临床试验(ClinicalTrials.gov标识符:NCT01897532)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have included limited numbers of patients with high CV risk and chronic kidney disease.

OBJECTIVE: To evaluate the effect of linagliptin, a selective DPP-4 inhibitor, on CV outcomes and kidney outcomes in patients with type 2 diabetes at high risk of CV and kidney events.

DESIGN, SETTING, AND PARTICIPANTS: Randomized, placebo-controlled, multicenter noninferiority trial conducted from August 2013 to August 2016 at 605 clinic sites in 27 countries among adults with type 2 diabetes, hemoglobin A1c of 6.5% to 10.0%, high CV risk (history of vascular disease and urine-albumin creatinine ratio [UACR] >200 mg/g), and high renal risk (reduced eGFR and micro- or macroalbuminuria). Participants with end-stage renal disease (ESRD) were excluded. Final follow-up occurred on January 18, 2018.

INTERVENTIONS: Patients were randomized to receive linagliptin, 5 mg once daily (n = 3494), or placebo once daily (n = 3485) added to usual care. Other glucose-lowering medications or insulin could be added based on clinical need and local clinical guidelines.

MAIN OUTCOMES AND MEASURES: Primary outcome was time to first occurrence of the composite of CV death, nonfatal myocardial infarction, or nonfatal stroke. Criteria for noninferiority of linagliptin vs placebo was defined by the upper limit of the 2-sided 95% CI for the hazard ratio (HR) of linagliptin relative to placebo being less than 1.3. Secondary outcome was time to first occurrence of adjudicated death due to renal failure, ESRD, or sustained 40% or higher decrease in eGFR from baseline.

RESULTS: Of 6991 enrollees, 6979 (mean age, 65.9 years; eGFR, 54.6 mL/min/1.73 m2; 80.1% with UACR >30 mg/g) received at least 1 dose of study medication and 98.7% completed the study. During a median follow-up of 2.2 years, the primary outcome occurred in 434 of 3494 (12.4%) and 420 of 3485 (12.1%) in the linagliptin and placebo groups, respectively, (absolute incidence rate difference, 0.13 [95% CI, -0.63 to 0.90] per 100 person-years) (HR, 1.02; 95% CI, 0.89-1.17; P < .001 for noninferiority). The kidney outcome occurred in 327 of 3494 (9.4%) and 306 of 3485 (8.8%), respectively (absolute incidence rate difference, 0.22 [95% CI, -0.52 to 0.97] per 100 person-years) (HR, 1.04; 95% CI, 0.89-1.22; P = .62). Adverse events occurred in 2697 (77.2%) and 2723 (78.1%) patients in the linagliptin and placebo groups; 1036 (29.7%) and 1024 (29.4%) had 1 or more episodes of hypoglycemia; and there were 9 (0.3%) vs 5 (0.1%) events of adjudication-confirmed acute pancreatitis.

CONCLUSIONS AND RELEVANCE: Among adults with type 2 diabetes and high CV and renal risk, linagliptin added to usual care compared with placebo added to usual care resulted in a noninferior risk of a composite CV outcome over a median 2.2 years.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01897532.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Rosenstock J, Perkovic V, Johansen OE, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019. PMID: 30418475. doi:10.1001/jama.2018.18269

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。